Axcella Health  logo
Axcella Health AXLA

Quarterly report 2023-Q2
added 08-03-2023

report update icon

Axcella Health Income Statement 2011-2026 | AXLA

Annual Income Statement Axcella Health

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

25 M 65.2 M 201 M 80.6 M - - - - - - - -

Shares

54.4 M 38.1 M 36.9 M 16.6 M - - - - - - - -

Historical Prices

0.46 1.71 5.44 4.84 - - - - - - - -

Net Income

-81.2 M -64.6 M -56.5 M -59 M -36.1 M -30.9 M - - - - - -

Operating Income

-77 M -61.8 M -53.8 M -57.4 M -33.9 M - - - - - - -

Interest Expense

3.02 M 2.92 M 10 K 3.4 M 2.78 M - - - - - - -

EBITDA

-76.6 M -61.6 M -53.1 M -56.8 M -32.8 M -27.6 M - - - - - -

Operating Expenses

77 M 61.8 M 53.8 M 57.4 M - - - - - - - -

General and Administrative Expenses

15.8 M 18.7 M 16.8 M 15.8 M 8.41 M 6 M - - - - - -

All numbers in USD currency

Quarterly Income Statement Axcella Health

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

73.7 M 73.7 M 73.7 M 52.6 M 52.6 M 41.4 M 39.2 M 38.2 M 37.7 M 37.7 M 37.6 M 36.9 M 29.2 M 23.2 M 23.2 M 23.1 M 15.2 M 4.78 M 4.77 M 4.77 M 4.41 M 4.23 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-3.41 M -3.98 M - -17.8 M -21.3 M -19 M - -15.6 M -15.9 M -15.2 M - -12.4 M -13.9 M -15 M - -17.3 M -14.4 M -11.6 M - -8.78 M -9.42 M -8.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - 257 K - - - 390 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-3.54 M -4.18 M - -17.1 M -20.6 M -18.3 M - -14.9 M -15.2 M -14.5 M - -11.7 M -13.2 M -14.5 M - -17 M -14.1 M -11 M - -8.23 M -8.91 M -7.59 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-2 K 67 K - -43 K - -27 K - - -5 K - - -5 K 2 K 802 K - -307 K -376 K 881 K - -550 K -515 K -509 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- -4.17 M - -16.8 M -20.5 M -18.3 M - -14.7 M -15.1 M -14.4 M - -11.4 M -12.9 M -14.3 M - -16.5 M -13.7 M -10.8 M - -7.38 M -8.28 M -7.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

3.54 M 4.18 M - 17.1 M 20.6 M 18.3 M - 14.9 M 15.2 M 14.5 M - 11.7 M 13.2 M 14.5 M - 17 M 14.1 M 11 M - 8.23 M 8.91 M 7.59 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

2.32 M 2.75 M - 3.78 M 3.75 M 4.79 M - 4.77 M 4.95 M 4.26 M - 4.18 M 4.62 M 4.12 M - 4.84 M 4.73 M 3.47 M - 2.09 M 2.9 M 2.14 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Axcella Health (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 219.89 2.02 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Omeros Corporation Omeros Corporation
OMER
$ 10.41 2.26 % $ 606 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.54 1.61 % $ 913 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 2.33 - $ 3.05 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.32 - $ 337 M britainBritain
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 10.41 3.48 % $ 759 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.29 1.28 % $ 110 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 47.2 1.66 % $ 4.24 B schweizSchweiz
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 1.31 1.95 % $ 80.4 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
$ 1.38 -1.08 % $ 72.5 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.46 3.48 % $ 855 M canadaCanada
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.28 4.97 % $ 252 M usaUSA